TY - JOUR AU - Gladman, D. D. AU - Antoni, C. AU - Mease, P. AU - Clegg, D. O. AU - Nash, P. PY - 2005 DA - 2005// TI - Psoriatic arthritis: epidemiology, clinical features, course, and outcome JO - Ann Rheum Dis VL - 64 ID - Gladman2005 ER - TY - JOUR AU - Finlay, A. Y. AU - Khan, G. K. PY - 1994 DA - 1994// TI - Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use JO - Clin Exp Dermatol VL - 19 UR - https://doi.org/10.1111/j.1365-2230.1994.tb01167.x DO - 10.1111/j.1365-2230.1994.tb01167.x ID - Finlay1994 ER - TY - JOUR AU - Hewlett, S. AU - Dures, E. AU - Almeida, C. PY - 2011 DA - 2011// TI - Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS) JO - Arthritis Care Res (Hoboken) VL - 63 UR - https://doi.org/10.1002/acr.20579 DO - 10.1002/acr.20579 ID - Hewlett2011 ER - TY - JOUR AU - Husted, J. A. AU - Gladman, D. D. AU - Long, J. A. AU - Farewell, V. T. PY - 1995 DA - 1995// TI - A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis JO - Clin Exp Rheumatol VL - 13 ID - Husted1995 ER - TY - JOUR AU - Husted, J. A. AU - Gladman, D. D. AU - Farewell, V. T. AU - Long, J. A. AU - Cook, R. J. PY - 1997 DA - 1997// TI - Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis JO - J Rheumatol VL - 24 ID - Husted1997 ER - TY - JOUR AU - Mease, P. J. PY - 2011 DA - 2011// TI - Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI) JO - Arthritis Care Res (Hoboken) VL - 63 UR - https://doi.org/10.1002/acr.20577 DO - 10.1002/acr.20577 ID - Mease2011 ER - TY - JOUR AU - Bruce, B. AU - Fries, J. F. PY - 2003 DA - 2003// TI - The Stanford Health Assessment Questionnaire: dimensions and practical applications JO - Health Qual Life Outcomes VL - 1 UR - https://doi.org/10.1186/1477-7525-1-20 DO - 10.1186/1477-7525-1-20 ID - Bruce2003 ER - TY - JOUR AU - Cutolo, M. AU - Nadler, S. PY - 2013 DA - 2013// TI - Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis JO - Autoimmun Rev VL - 12 UR - https://doi.org/10.1016/j.autrev.2013.01.001 DO - 10.1016/j.autrev.2013.01.001 ID - Cutolo2013 ER - TY - STD TI - Orencia Prescribing Information 2017 February 2, 2018. Available from: http://packageinserts.bms.com/pi/pi_orencia.pdf. Accessed 2 Feb 2018. UR - http://packageinserts.bms.com/pi/pi_orencia.pdf ID - ref9 ER - TY - JOUR AU - Mease, P. J. AU - Gottlieb, A. B. AU - van der Heijde, D. AU - FitzGerald, O. AU - Johnsen, A. AU - Nys, M. PY - 2017 DA - 2017// TI - Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis JO - Ann Rheum Dis VL - 76 UR - https://doi.org/10.1136/annrheumdis-2016-210724 DO - 10.1136/annrheumdis-2016-210724 ID - Mease2017 ER - TY - JOUR AU - Gossec, L. AU - Smolen, J. S. AU - Ramiro, S. AU - de Wit, M. AU - Cutolo, M. AU - Dougados, M. PY - 2016 DA - 2016// TI - European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update JO - Ann Rheum Dis VL - 75 UR - https://doi.org/10.1136/annrheumdis-2015-208337 DO - 10.1136/annrheumdis-2015-208337 ID - Gossec2016 ER - TY - JOUR AU - Taylor, W. AU - Gladman, D. AU - Helliwell, P. AU - Marchesoni, A. AU - Mease, P. AU - Mielants, H. PY - 2006 DA - 2006// TI - Classification criteria for psoriatic arthritis: development of new criteria from a large international study JO - Arthritis Rheum VL - 54 UR - https://doi.org/10.1002/art.21972 DO - 10.1002/art.21972 ID - Taylor2006 ER - TY - JOUR AU - Gladman, D. D. AU - Mease, P. J. AU - Cifaldi, M. A. AU - Perdok, R. J. AU - Sasso, E. AU - Medich, J. PY - 2007 DA - 2007// TI - Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial JO - Ann Rheum Dis VL - 66 UR - https://doi.org/10.1136/ard.2006.057901 DO - 10.1136/ard.2006.057901 ID - Gladman2007 ER - TY - JOUR AU - Mease, P. J. AU - Woolley, J. M. AU - Bitman, B. AU - Wang, B. C. AU - Globe, D. R. AU - Singh, A. PY - 2011 DA - 2011// TI - Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction JO - J Rheumatol VL - 38 UR - https://doi.org/10.3899/jrheum.110546 DO - 10.3899/jrheum.110546 ID - Mease2011 ER - TY - JOUR AU - Kosinski, M. AU - Zhao, S. Z. AU - Dedhiya, S. AU - Osterhaus, J. T. AU - Ware, J. E. PY - 2000 DA - 2000// TI - Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis JO - Arthritis Rheum VL - 43 UR - https://doi.org/3.0.CO;2-M DO - 3.0.CO;2-M ID - Kosinski2000 ER - TY - JOUR AU - Shikiar, R. AU - Willian, M. K. AU - Okun, M. M. AU - Thompson, C. S. AU - Revicki, D. A. PY - 2006 DA - 2006// TI - The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study JO - Health Qual Life Outcomes VL - 4 UR - https://doi.org/10.1186/1477-7525-4-71 DO - 10.1186/1477-7525-4-71 ID - Shikiar2006 ER - TY - JOUR AU - Strand, V. AU - Mease, P. AU - Burmester, G. R. AU - Nikaï, E. AU - Coteur, G. AU - van Vollenhoven, R. PY - 2009 DA - 2009// TI - Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial JO - Arthritis Res Ther VL - 11 UR - https://doi.org/10.1186/ar2859 DO - 10.1186/ar2859 ID - Strand2009 ER - TY - JOUR AU - Krishnan, E. AU - Sokka, T. AU - Häkkinen, A. AU - Hubert, H. AU - Hannonen, P. PY - 2004 DA - 2004// TI - Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population JO - Arthritis Rheum VL - 50 UR - https://doi.org/10.1002/art.20048 DO - 10.1002/art.20048 ID - Krishnan2004 ER - TY - JOUR AU - Strand, V. AU - Rentz, A. M. AU - Cifaldi, M. A. AU - Chen, N. AU - Roy, S. AU - Revicki, D. PY - 2012 DA - 2012// TI - Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study JO - J Rheumatol VL - 39 UR - https://doi.org/10.3899/jrheum.101161 DO - 10.3899/jrheum.101161 ID - Strand2012 ER - TY - JOUR AU - Revicki, D. A. AU - Menter, A. AU - Feldman, S. AU - Kimel, M. AU - Harnam, N. AU - Willian, M. K. PY - 2008 DA - 2008// TI - Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study JO - Health Qual Life Outcomes VL - 6 UR - https://doi.org/10.1186/1477-7525-6-75 DO - 10.1186/1477-7525-6-75 ID - Revicki2008 ER - TY - JOUR AU - Webster, K. AU - Cella, D. AU - Yost, K. PY - 2003 DA - 2003// TI - The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation JO - Health Qual Life Outcomes VL - 1 UR - https://doi.org/10.1186/1477-7525-1-79 DO - 10.1186/1477-7525-1-79 ID - Webster2003 ER - TY - JOUR AU - Strand, V. AU - Boers, M. AU - Idzerda, L. AU - Kirwan, J. R. AU - Kvien, T. K. AU - Tugwell, P. S. PY - 2011 DA - 2011// TI - It's good to feel better but it’s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10 JO - J Rheumatol VL - 38 UR - https://doi.org/10.3899/jrheum.110392 DO - 10.3899/jrheum.110392 ID - Strand2011 ER - TY - JOUR AU - Mease, P. AU - van der Heijde, D. AU - Landewé, R. PY - 2018 DA - 2018// TI - Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study JO - Ann Rheum Dis VL - 77 ID - Mease2018 ER - TY - JOUR AU - Strand, V. AU - Sharp, V. AU - Koenig, A. S. AU - Park, G. AU - Shi, Y. AU - Wang, B. PY - 2012 DA - 2012// TI - Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment JO - Ann Rheum Dis VL - 71 UR - https://doi.org/10.1136/annrheumdis-2011-200387 DO - 10.1136/annrheumdis-2011-200387 ID - Strand2012 ER - TY - JOUR AU - Mease, P. J. AU - Woolley, J. M. AU - Singh, A. AU - Tsuji, W. AU - Dunn, M. AU - Chiou, C. F. PY - 2010 DA - 2010// TI - Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis JO - J Rheumatol VL - 37 UR - https://doi.org/10.3899/jrheum.091093 DO - 10.3899/jrheum.091093 ID - Mease2010 ER - TY - JOUR AU - Fleischmann, R. AU - Weinblatt, M. E. AU - Schiff, M. AU - Khanna, D. AU - Maldonado, M. A. AU - Nadkarni, A. PY - 2015 DA - 2015// TI - Patient-reported outcomes from a two-year head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis JO - Arthritis Care Res (Hoboken) VL - 68 UR - https://doi.org/10.1002/acr.22763 DO - 10.1002/acr.22763 ID - Fleischmann2015 ER - TY - JOUR AU - Rahman, P. AU - Puig, L. AU - Gottlieb, A. B. AU - Kavanaugh, A. AU - McInnes, I. AU - Ritchlin, C. PY - 2013 DA - 2013// TI - SAT0264 ustekinumab improves physical function, quality of life and work productivity of patients with active psoriatic arthritis who were naÏve to MTX, despite MTX therapy or previously treated with anti-TNF: results from Psummit I and Psummit II JO - Ann Rheum Dis VL - 72 UR - https://doi.org/10.1136/annrheumdis-2013-eular.1989 DO - 10.1136/annrheumdis-2013-eular.1989 ID - Rahman2013 ER - TY - JOUR AU - Ritchlin, C. AU - Rahman, P. AU - Kavanaugh, A. AU - McInnes, I. B. AU - Puig, L. AU - Li, S. PY - 2014 DA - 2014// TI - Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial JO - Ann Rheum Dis VL - 73 UR - https://doi.org/10.1136/annrheumdis-2013-204655 DO - 10.1136/annrheumdis-2013-204655 ID - Ritchlin2014 ER - TY - JOUR AU - McInnes, I. B. AU - Mease, P. J. AU - Kirkham, B. AU - Kavanaugh, A. AU - Ritchlin, C. T. AU - Rahman, P. PY - 2015 DA - 2015// TI - Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial JO - Lancet VL - 386 UR - https://doi.org/10.1016/S0140-6736(15)61134-5 DO - 10.1016/S0140-6736(15)61134-5 ID - McInnes2015 ER - TY - JOUR AU - Strand, V. AU - Mease, P. AU - Gossec, L. AU - Elkayam, O. AU - Van den Bosch, F. AU - Zuazo, J. PY - 2017 DA - 2017// TI - Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1) JO - Ann Rheum Dis VL - 76 UR - https://doi.org/10.1136/annrheumdis-2015-209055 DO - 10.1136/annrheumdis-2015-209055 ID - Strand2017 ER - TY - JOUR AU - Kavanaugh, A. AU - Mease, P. J. AU - Gomez-Reino, J. J. AU - Adebajo, A. O. AU - Wollenhaupt, J. AU - Gladman, D. D. PY - 2014 DA - 2014// TI - Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor JO - Ann Rheum Dis VL - 73 UR - https://doi.org/10.1136/annrheumdis-2013-205056 DO - 10.1136/annrheumdis-2013-205056 ID - Kavanaugh2014 ER - TY - JOUR AU - Højgaard, P. K. L. AU - Orbai, A. M. AU - Holmsted, K. AU - Bartels, E. M. AU - Leung, Y. Y. AU - Goel, N. AU - de Wit, M. AU - Gladman, D. D. AU - Mease, P. AU - Dreyer, L. AU - Kristensen, L. E. AU - FitzGerald, O. AU - Tillett, W. AU - Gossec, L. AU - Helliwell, P. AU - Strand, V. AU - Ogdie, A. AU - Terwee, C. B. AU - Christensen, R. PY - 2018 DA - 2018// TI - A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative JO - Semin Arthritis Rheum VL - 47 UR - https://doi.org/10.1016/j.semarthrit.2017.09.002 DO - 10.1016/j.semarthrit.2017.09.002 ID - Højgaard2018 ER - TY - STD TI - Mease P, Strand V, Gladman D. Functional impairment measurement in psoriatic arthritis: Importance and challenges. Semin Arthritis Rheum. 2018. https://doi.org/10.1016/j.semarthrit.2018.05.010. ID - ref33 ER - TY - CHAP AU - Ware, J. E. AU - Kosinski, M. PY - 2001 DA - 2001// BT - SF-36 Physical & Mental Health Summary Scales: A Manual for Users of Version 1 PB - QualityMetric Incorporated CY - Lincoln ID - Ware2001 ER -